This human FXN YAC transgenic mouse model has the mouse frataxin knockout allele (Fxn-) and the human FXN YAC transgene from founder YG8 (carrying two tandem copies of the human FXN gene with ~82 and ~190 GAA trinucleotide sequence repeats). Mice homozygous for the knockout and hemizygous for the YG8 transgene, called YG8R mice, are rescued from knockout lethality and have transgene expression that models the phenotype of Friedreich's Ataxia (FRDA).
Our preclinical efficacy testing services offer scientific expertise and an array of target-based and phenotype-based outcome measures, both in vivo and at endpoint, for flexible study designs and assay development in mouse models of Friedreich's Ataxia. See our full service platform.
Mark A Pook, Brunel University
Genetic Background | Generation |
---|---|
|
Allele Type | Gene Symbol | Gene Name |
---|---|---|
Targeted (Null/Knockout) | Fxn | frataxin |
Allele Type |
---|
Transgenic (Inserted expressed sequence, Humanized sequence) |
This strain is maintained heterozygous for the targeted mutation and hemizygous for the transgene.
Importation of this model was supported by the Friedreich's Ataxia Research Alliance (FARA).
The YG8 transgenic founder line carries two tandem copies of the human FXN gene with ~82 and ~190 GAA trinucleotide sequence repeats. Mice that are heterozygous for the Fxn- knockout allele and hemizygous for the YG8 transgene are viable and fertile. High levels of human FXN gene product (mRNA or protein) are detected by RT-PCR and Western blot analysis. Approximately 40-50% of the endogenous mouse Fxn gene product (protein) is detected by Western blot analysis in mice heterozygous for the Fxn- knockout allele alone. Mice homozygous for the Fxn- knockout allele and hemizygous for the YG8 transgene, called YG8R mice, are rescued from knockout lethality and have transgene expression that results in an age-dependent, tissue-specific expansion of the GAA repeat, with expansion accumulation observed in the CNS (particularly cerebellum), similar to the human pathology of Friedreich's Ataxia. The GAA triplet repeats exhibit intergenerational instability.
In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. This is the case for the strain above. It should be noted that the phenotype could vary from that originally described. We will modify the strain description if necessary as published results become available.
It should be noted that the YAC transgenic FRDA mouse models available from The Jackson Laboratory (YG22R, YG8R and YG8sR) may have different GAA repeat sizes than the animals used in the publications described below.
Publications
from Dr. Mark A. Pook (Brunel University London) in 2014-2015 examine the correlation between the FRDA-like pathological phenotype and frataxin-deficiency in the YAC transgenic FRDA mouse models YG22R (two copies of the FRDA transgene; 190 GAA repeats expanded to ~170-260), YG8R (two copies of the FRDA transgene; 90-190 GAA repeats expanded to ~120-220) and YG8sR (a contraction of the transgene to a single copy; ~120-150 GAA repeats) compared to Y47R control mice (one copy of the FRDA transgene with a stable 9 GAA repeat) and C57BL6/J wildtype mice. The results described below are all in comparison to control mice.
The three YAC transgenic FRDA mouse models (YG8R, YG22R and YG8sR) had a progressive decrease in the motor coordination; the degree of impairment was most significant in YG8R mice. All three models exhibited GAA repeat somatic instability in the brain, cerebellum and liver, as well as exhibited glucose intolerance and insulin hypersensitivity. The greatest FXN deficiency of the three models tested was in YG8sR. Expression levels of the transgenes in various tissues are reported in the Pook publications.
These double mutant mice, heterozygous for the targeted mutation and hemizygous for the transgene, were generated by crossing transgenic mice (founder line YG8) with Fxntm1Mkn targeted mutant mice.
Drs. Michel Koenig and Helene Puccio generated the Fxn targeted mutation allele by disrupting exon 4 and flanking sequences with a loxP site flanked PGK-neo cassette. The construct was electroporated into 129/Sv derived embryonic stem (ES) cells. Correctly targeted ES cells were injected into C57BL/6J blastocysts. The resulting chimeric animals were crossed to C57BL/6J mice, and then backcrossed to C57BL/6J for five generations.
The transgenic construct consisting of a 370kb YAC insert that includes the entire human FXN gene with GAA triplet repeat sequences, was injected into fertilized CBA X C57BL/6 hybrid fertilized oocytes. Founder line YG8 was established, carrying 2 tandem copies of the human FXN gene with GAA trinucleotide sequence repeats as low as 122 and as high as 207. Founder animals were bred to wildtype C57BL/6J mice for five generations.
The two lines were then crossed to generate the double mutant. The Donating Investigator breeds mice that are heterozygous for the Fxntm1Mkn targeted mutation and hemizygous for the YG8 transgene to mice that are heterozygous for the Fxntm1Mkn targeted mutation to obtain mice homozygous for the Fxntm1Mkn targeted mutation and hemizygous for the YG8 transgene.
SNP (single nucleotide polymorphism) analysis performed by The Jackson Laboratory revealed that the mice originally imported were on a mixed genetic background. The mixed genetic background mice were then backcrossed to C57BL/6J for five generations.
Expressed Gene | Fxn, frataxin, mouse, laboratory |
---|---|
Site of Expression | |
Expressed Gene | FXN, frataxin, human |
Site of Expression |
Allele Name | targeted mutation 1, Michel Koenig |
---|---|
Allele Type | Targeted (Null/Knockout) |
Allele Synonym(s) | Frda-; Frdadel4 |
Gene Symbol and Name | Fxn, frataxin |
Gene Synonym(s) | |
Expressed Gene | Fxn, frataxin, mouse, laboratory |
Strain of Origin | 129/Sv |
Chromosome | 19 |
Molecular Note | A loxP-flanked PGK-neomycin resistance cassette replaced a genomic DNA fragment containing exon 4, which is highly conserved and often mutated in humans. An additional line was also produced in which the loxP flanked neomycin cassette was removed by Cre mediated recombination, but no distinction was made between these alleles in the original reference. From J:90098: The presence of a human FRDA transgene in hemizygous form in a Frdatm1Mkn homozygous null background rescues the embryonic lethal phenotype and complements for the loss of endogenous mouse frataxin. |
Allele Name | transgene insertion YG8, Mark A Pook |
---|---|
Allele Type | Transgenic (Inserted expressed sequence, Humanized sequence) |
Allele Synonym(s) | YG8 |
Gene Symbol and Name | Tg(FXN)YG8Pook, transgene insertion YG8, Mark A Pook |
Gene Synonym(s) | |
Promoter | FXN, frataxin, human |
Expressed Gene | FXN, frataxin, human |
Strain of Origin | CBA x C57BL/6 |
Chromosome | UN |
General Note | Line YG22 exhibits slightly greater age-related repeat instability, with a bias toward repeat expansion. |
Molecular Note | The transgenic construct consists of a 370kb YAC insert that includes the entire human FXN gene with GAA triplet repeat sequences, and was injected into fertilized CBA X C57BL/6 hybrid fertilized oocytes. Founder line YG8 was established, carrying 2 tandem copies of the human FXN gene with two GAA trinucleotide repeat sequences of 82 and 190 repeats. This line displayed a transmission rate of 52% to offspring. |
When maintaining a live colony, these mice can be bred as heterozygotes for the targeted mutation and hemizygotes for the transgene.
When using the B6.Cg-Fxntm1Mkn Tg(FXN)YG8Pook/J mouse strain in a publication, please cite the originating article(s) and include JAX stock #012253 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Heterozygous or wild-type for Fxn<tm1Mkn> , Hemizygous or Non Carrier for Tg(FXN)YG8Pook |
Frozen Mouse Embryo | B6.Cg-Fxn<tm1Mkn> Tg(FXN)YG8Pook/J | $2595.00 |
Frozen Mouse Embryo | B6.Cg-Fxn<tm1Mkn> Tg(FXN)YG8Pook/J | $2595.00 |
Frozen Mouse Embryo | B6.Cg-Fxn<tm1Mkn> Tg(FXN)YG8Pook/J | $3373.50 |
Frozen Mouse Embryo | B6.Cg-Fxn<tm1Mkn> Tg(FXN)YG8Pook/J | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.